Cardio Selling General Administrative from 2010 to 2024

CDIOW Stock  USD 0.04  0  9.24%   
Cardio Diagnostics Selling General Administrative yearly trend continues to be fairly stable with very little volatility. Selling General Administrative is likely to outpace its year average in 2024. During the period from 2010 to 2024, Cardio Diagnostics Selling General Administrative regression line of quarterly data had mean square error of 3.3 T and geometric mean of  927,720. View All Fundamentals
 
Selling General Administrative  
First Reported
2010-12-31
Previous Quarter
6.9 M
Current Value
7.3 M
Quarterly Volatility
2.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cardio Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardio Diagnostics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 117.2 K or Selling General Administrative of 7.3 M, as well as many indicators such as Price To Sales Ratio of 1.8 K, Dividend Yield of 0.0 or PTB Ratio of 10.14. Cardio financial statements analysis is a perfect complement when working with Cardio Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Cardio Diagnostics Correlation against competitors.

Latest Cardio Diagnostics' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Cardio Diagnostics Holdings over the last few years. It is Cardio Diagnostics' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardio Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Cardio Selling General Administrative Regression Statistics

Arithmetic Mean1,706,511
Geometric Mean927,720
Coefficient Of Variation140.88
Mean Deviation1,800,112
Median591,521
Standard Deviation2,404,102
Sample Variance5.8T
Range6.8M
R-Value0.69
Mean Square Error3.3T
R-Squared0.47
Significance0
Slope369,551
Total Sum of Squares80.9T

Cardio Selling General Administrative History

20247.3 M
20236.9 M
20224.4 M
2021470.6 K

About Cardio Diagnostics Financial Statements

Cardio Diagnostics investors use historical fundamental indicators, such as Cardio Diagnostics' Selling General Administrative, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cardio Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative6.9 M7.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cardio Stock Analysis

When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.